SweetValueLab
Write for us

IQVIA Holdings Inc. — Wall Street Analyst Estimates & Price Targets

IQV
NYSEHealthcareMedical - Diagnostics & ResearchCIK 0001478242iqvia.comAbout IQV
Last close · Oct 16, 2026266.90−4.14 (−1.53%)
Market cap$43.9B

9 firms' latest targets, last 90 days: median $300.00 ($247.00–$345.00), 12% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker
$150$200$250$300$350NovJan 2026MarMayJulSep2025-10-29 · Stifel: $2542025-10-29 · UBS: $2502025-10-29 · Baird: $2582025-12-01 · Morgan Stanley: $2652025-12-15 · Barclays: $2302026-01-08 · UBS: $2802026-01-08 · Truist: $2902026-01-09 · Mizuho Securities: $2662026-02-05 · Evercore ISI: $2252026-02-06 · UBS: $2402026-02-06 · BMO Capital: $2502026-02-06 · Stifel: $2202026-02-06 · Barclays: $2102026-02-11 · Morgan Stanley: $2402026-02-19 · Truist: $2452026-02-23 · Mizuho Securities: $2152026-04-08 · Evercore ISI: $1852026-05-07 · Morgan Stanley: $2252026-06-03 · HSBC: $2102026-06-17 · Morgan Stanley: $2002026-07-01 · Baird: $2492026-07-06 · HSBC: $2402026-07-09 · Deutsche Bank: $2402026-07-13 · Mizuho Securities: $2302026-07-29 · RBC Capital: $2472026-07-29 · BMO Capital: $2702026-07-29 · Baird: $2872026-09-17 · Morgan Stanley: $2702026-09-28 · Truist: $3292026-09-30 · UBS: $3452026-10-07 · Mizuho Securities: $3002026-10-07 · Barclays: $3002026-10-14 · Stifel: $303
$150$200$250$300$350NovFebMayAug

Each firm's latest target

last 90 days · 9 firms
DateFirmTargetPreviousChangeVs price thenVs price now
2026-10-14Stifel$303.00$220.00▲ 38%+16%+14%
2026-10-07Mizuho Securities$300.00$230.00▲ 30%+15%+12%
2026-10-07Barclays$300.00$210.00▲ 43%+15%+12%
2026-09-30UBS$345.00$240.00▲ 44%+28%+29%
2026-09-28Truist$329.00$245.00▲ 34%+22%+23%
2026-09-17Morgan Stanley$270.00$200.00▲ 35%+0%+1%
2026-07-29RBC Capital$247.00——+0%-7%
2026-07-29BMO Capital$270.00$250.00▲ 8%+8%+1%
2026-07-29Baird$287.00$249.00▲ 15%+18%+8%

Consensus estimates

revenue and EPS by fiscal year · reported years marked
FYRevenueYoYEPSYoYRevenue rangeEPS rangeAnalysts
2023reported$15.0B+4%$7.29+27%est. $14.9B+0%est. $10.1914
2024reported$15.4B+3%$7.49+3%est. $15.4B+0%est. $11.1216
2025reported$16.3B+6%$7.84+5%est. $16.2B+1%est. $11.8915
2026$17.4B+7%$12.94+9%$17.4B–$17.5B$12.89–$13.0016
2027$18.4B+6%$14.40+11%$18.2B–$19.0B$13.94–$15.0616
2028$19.5B+6%$16.15+12%$19.2B–$20.7B$14.11–$18.7715
2029$20.8B+6%$18.30+13%$20.6B–$21.3B$18.10–$18.9010
2030$22.2B+7%$20.67+13%$22.1B–$22.8B$20.44–$21.357
A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.